Senores Pharmaceuticals Ltd. was incorporated on December 26, 2017. The company is engaged in the the business of developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
| Bidding Dates |
|---|
| 20 Dec 2024 - 24 Dec 2024 |
| Subscription |
|---|
| 93.41x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,136 | 1 | 13 | 38 | 14.9 M | ₹372 - ₹391 | 45.76 % | ₹5538.2 M - ₹5821.1 M | RHP DOC |
Senores Pharmaceuticals Ltd. IPO SUBSCRIPTION STATUS
24 Dec '24Senores Pharmaceuticals Ltd. IPO overall subscription rate was 93.41 times the total available shares
Senores Pharmaceuticals Ltd. IPO retail subscription rate was 89.23 times in the retail segment
Senores Pharmaceuticals Ltd. IPO non-institutional investor subscription rate was 96.11 times in the non-institutional investor category
Senores Pharmaceuticals Ltd. IPO Qualified Institutional Bidder subscription rate was 94.66 times the available shares for Qualified Institutional Bidder
Senores Pharmaceuticals Ltd. IPO Employees subscription rate was 19.92 times in the Employees category
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers | Employees |
|---|---|---|---|---|
| Category Reservation | 10% | 15% | 75% | - |
24 Dec 2024 (Day 3) | 89.23x | 96.11x | 94.66x | 19.92x |
23 Dec 2024 (Day 2) | 38.41x | 24.63x | 0.35x | 10.14x |
20 Dec 2024 (Day 1) | 7.2x | 1.67x | 0.01x | 1.88x |
Senores Pharmaceuticals Ltd. FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| H1FY25 | 239.4 | 1,810.2 | 63.9 | -484.6 | 25.9% |
| FY24 | 327.1 | 2,145.2 | -198.7 | -717.0 | 20.7% |
| FY23 | 84.3 | 353.4 | -10.8 | -483.6 | 46.3% |
| FY22 | 9.9 | 141.7 | -104.5 | -211.3 | 17.0% |
Senores Pharmaceuticals Ltd. IPO SUBSCRIPTION STATUS DETAILS
Senores Pharmaceuticals Ltd. had 14.9 M shares on offer
Senores Pharmaceuticals Ltd. IPO offer price was in the range ₹372 - ₹391
Senores Pharmaceuticals Ltd. IPO minimum Investment was ₹14136
Senores Pharmaceuticals Ltd. IPO issue size was ₹ 5538.2 M - ₹ 5821.1 M
Senores Pharmaceuticals Ltd. had a minimum lot size of 38 Shares per application
Senores Pharmaceuticals Ltd. NUMBER OF SHARES ON OFFER
Senores Pharmaceuticals Ltd. IPO IMPORTANT DATES
| Issue Open Date | 20 Dec 2024 |
| Issue close Date | 24 Dec 2024 |
| Allotment Date | 26 Dec 2024 |
| Refund Date | 26 Dec 2024 |
| Demat Account Credit Date | 27 Dec 2024 |
| Listing Date | 30 Dec 2024 |
| Listing on Exchange(s) | NSE and BSE |
| Senores Pharmaceuticals Ltd. Allotment Status | Exchange |
Senores Pharmaceuticals Ltd. IPO subscription opened on 20 Dec 2024, and closed on 24 Dec 2024
IPO allotment for Senores Pharmaceuticals Ltd. was finalized on Thursday, 26 Dec 2024
IPO listing for Senores Pharmaceuticals Ltd. was on NSE and BSE on Monday, 30 Dec 2024
Senores Pharmaceuticals Ltd. IPO LISTING GAINS
| Issue Price (adjusted) | 391.0 |
| Listing Open Price | 600.0 |
| Listing Close Price | 557.0 |
| Listing Gain% | 53.5% |
| Current Gain% | 243.4% |
Senores Pharmaceuticals Ltd. Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Senores Pharmaceuticals Ltd. | 1342.6 | 6183.2 | 48.9 | 0.6 | 8.9 | 12.4 | 7.2 | 679.7 | 62.8 | 115.4 | 97 | 27.4 | 87 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Senores Pharmaceuticals Ltd. IPO Reports
Senores Pharmaceuticals Ltd. INFORMATION ON IPO ISSUE
About Senores Pharmaceuticals Ltd.
Senores Pharmaceuticals Ltd. was incorporated on December 26, 2017. The company is engaged in the the business of developing and manufacturing a wide range of pharmaceutical products predominantly for Regulated Markets across various therapeutic areas and dosage forms.
Object of the Issue
- Funding capital expenditure requirements by investment in a subsidiary, Havix Group, Inc. d/b/a Aavis Pharmaceuticals (“Havix”), to set up a manufacturing facility for the production of sterile injections in the Atlanta Facility
- Repayment/pre-payment, in full or in part, of certain borrowings availed by the company and its subsidiaries, Havix, Ratnatris Pharmaceutical (“Ratnatris”), and Senores Pharmaceuticals Inc. (“SPI”)
- Funding the working capital requirements of the company and its subsidiaries, SPI and Ratnatris
- Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes.
Senores Pharmaceuticals Ltd. - PROMOTERS
| Name |
|---|
| Swapnil Jatinbhai Shah |
| Ashokkumar Vijaysinh Barot |
Senores Pharmaceuticals Ltd. Book Running Lead Managers
Equirus Capital Private Limited
senores.ipo@equirus.com
Ambit Private Limited
senores.ipo@ambit.co
Nuvama Wealth Management Limited
senores@nuvama.com
Senores Pharmaceuticals Ltd. Registrar to the Issue
Link Intime India Private Limited
senorespharma.ipo@linkintime.co.in
Senores Pharmaceuticals Ltd. Strengths
US FDA approved facility
The company manufactures products for regulated markets through a US FDA-approved OSD facility in Atlanta, US. The Atlanta facility has a strong regulatory track record and has been audited and approved by the US FDA four times since the commencement of its operations.
Long-term arrangements
The company has entered into long-term marketing arrangements for a period ranging between 5-7 years with major generic pharmaceutical and marketing companies that operate in the regulated markets including Lannett Company Inc., Jubilant Cadista Pharmaceuticals Inc., and Sun Pharmaceuticals Industries.
Senores Pharmaceuticals Ltd. Risks
Dependent on third party partners
The company's business is dependent on the sale of products through third-party marketing partners and distributors. The loss of one or more marketing partners or distributors or the inability to maintain and increase the number of their arrangements for the marketing and distribution of its products could adversely affect the business, financial conditions, and cash flows.
Dependent on a few customers
The company derives a significant part of its revenue from a few customers. If one or more of such customers choose not to source their requirements from the company, or terminate its contracts or purchase orders, its financial condition and results of operations may be adversely affected.
Geographically concentrated
The company derives a significant portion of its revenue from its operations in the United States. A reduction in demand for its products in these regions could adversely affect the business
IPO FAQs
This IPO consists of an offer for sale of up to Rs 82.1 crore, of 2,100,000 shares. It also consists of a fresh issue of Rs 500.0 crore.
The promoters of the company are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
The category allocation of qualified institutional buyers is 75.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 10.0%.
The price band of the IPO is Rs 372.0 - 391.0.
The IPO application opens on Dec 20, 2024 and closes on Dec 24, 2024.
The minimum lot size for the IPO is 38. The maximum lot size for the IPO is 494.
For all category investors, the minimum application amount for this IPO is Rs. 14,136.0, the maximum value for this IPO is Rs 193,154.0.
This IPO will be allotted on Dec 26, 2024.
The refund will be credited to your account on Dec 26, 2024.
The allotted shares will be credited to your demat on Dec 27, 2024.
Senores Pharmaceuticals Ltd.’s shares listed on the stock exchanges on Dec 30, 2024.